Real-World Safety and Effectiveness of Evolocumab in Korean Patients with Atherosclerotic Cardiovascular Disease or Familial Hypercholesterolemia: A Post-Marketing Surveillance Study
Evolocumab effectively lowered LDL-C levels and had a favorable safety profile in Korean patients with ASCVD or FH. The incidence of AEs was lower than in clinical trials, and no ADRs were observed among the SAEs. These results support the use of evolocumab as a viable therapeutic option.
Authors
- Jin-Seok Jeong
- Donggyu Moon (ORCID: https://orcid.org/0000-0003-4927-3248)
- Osung Kwon (ORCID: https://orcid.org/0000-0001-6857-8632)
- Ki‐Dong Yoo (ORCID: https://orcid.org/0000-0001-5425-1102)
- Seung‐Ho Hur (ORCID: https://orcid.org/0000-0002-3895-1915)
- Sang Rok Lee (ORCID: https://orcid.org/0000-0002-5845-2232)
- Myung Ho Jeong (ORCID: https://orcid.org/0000-0003-2424-810X)
- Kyung Hoon Cho (ORCID: https://orcid.org/0000-0002-0377-6352)
Institutions
- The Catholic University of Korea St. Vincent's Hospital (KR)
- Chonnam National University Hospital (KR)
- Veterans Health Service Medical Center (KR)
- Keimyung University (KR)
- Jeonbuk National University (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Cardiology and Therapy
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1007/s40119-025-00430-8
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen